ABSTRACT ARTS (Sept4_i2) is a pro-apoptotic mitochondrial tumor suppressor protein which binds to and causes degradation of XIAP (X-linked inhibitor of apoptosis). We recently showed that ARTS brings XIAP into close proximity to Bcl-2, creating a complex which enables degradation of both these major anti-apoptotic proteins and promotes apoptosis. The possible therapeutic implications are discussed here.
mitochondria is caspase independent and can occur rapidly. Within minutes following apoptotic induction ARTS can translocate to the cytosol to bind to XIAP and cause de-repression of active caspases. 5 The function of ARTS is required for proper, on time MOMP and release of proteins in the mitochondrial inter-membrane space. Accordingly, Sept4/ARTSNull MEFs (Mouse Embryonal Fibroblasts) exhibit a significant delay in the release of cytochrome c and Smac/Diablo from the mitochondria following apoptotic induction 5 . Therefore, we suggest that this pre-MOMP ARTS-dependent release of active caspases enables cleavage of caspase substrates such as Bid that can now promotes MOMP. This also provides an explanation for many reports demonstrating a requirement for caspases to enable release of Smac/Diablo and MOMP (for example, 6 We have previously shown that ARTS acts as an XIAP antagonist). 1, 2 In addition, we identified a distinct mechanism by which ARTS promotes apoptosis through antagonizing Bcl-2 ( Fig. 1) . In living cells, ARTS is in a complex with Bcl-2 at the outer membrane of mitochondria, and XIAP and Bcl-2 do not bind to each other. However, upon induction of apoptosis ARTS serves as a scaffold to bring XIAP into close proximity with Bcl-2. This now allows XIAP to act as an E3-ligase and degrade Bcl-2 through the ubiquitin-proteasome system. 7 Lysine 17 in Bcl-2 is the major acceptor for ARTS and XIAPmediated ubiquitylation (Fig. 1) . In vivo ubiquitylation assays preformed in both XIAP and Sept4/ARTS null MEFs showed a significant inhibition of ubiquitylation of Bcl-2 upon induction of apoptosis. Moreover, mutating Lysine 17 to Alanine in Bcl-2 as well as mutating all 4 Lysines in Bcl-2 caused increased protein stability and more potent anti-apoptotic function. 7 The BH3 domain in Bcl-2 is known to mainly interact with BH3 domains of other Bcl-2 members. Interestingly, we showed that ARTS binds directly also to the BH3 domain of Bcl-2, and a mutant Bcl-2 protein lacking its BH3 domain had reduced binding to ARTS and significant decrease in its ability to undergo ubiquitylation. 7 Using a peptide array method, we found that ARTS binds to the same Bcl-2-BH3 binding pocket as the pro-apoptotic Bax protein. This suggests that Bcl-2 counteracts ARTS in living cells in a similar way to its interaction with Bax. In addition, Sept4/ARTS null MEFs and ARTS KD (knocked down cells) exhibit high levels of Bcl-2, suggesting that ARTS functions as a novel Bcl-2 antagonist. Interestingly, the BH3-mimetic ABT-199 can attenuate the interaction between Bcl-2 and ARTS, indicating that the specific BH3-binding motif to which ABT-199 binds in Bcl-2 is also important for the interaction with ARTS. This activity of ABT-199 is expected to reduce degradation of Bcl-2, which has the potential to cause increased resistance towards apoptosis. However, because ABT-199 causes cell killing it is clear that this compound potently inactivates the anti-apoptotic activity of Bcl-2, even if present at somewhat elevated levels.
Bcl-2 is over-expressed in hematological malignancies and solid tumors. 8 Likewise, XIAP is over-expressed in many cancers. 9 High XIAP expression has been correlated with resistance to chemotherapy and radiotherapy and to poor prognosis. Therefore, intense efforts have been made to target these two major anti-apoptotic proteins for cancer therapy. Moreover, simultaneous inhibition of both XIAP and Bcl-2 enhances killing of cancer cells in a nonlinear way and improves chemotherapy. 10 This suggests that ARTS-mimetic small molecules that could degrade both XIAP and Bcl-2 will be potentially very effective cancer therapeutics.
